Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies by Zamboni, William C. et al.
Phase I and Pharmacokinetic Study of Pegylated Liposomal
CKD-602 (S-CKD602) in Patients with Advanced Malignancies
William C. Zamboni1,2, Suresh Ramalingam3,4, David M. Friedland3, Robert P. Edwards5,6,
Ronald G. Stoller3, Sandra Strychor4, Lauren Maruca4, Beth A. Zamboni7, Chandra P.
Belani3,4, and Ramesh K. Ramanathan3,4
1 Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy,
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
2 Molecular Therapeutics, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599
3 Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of
Pittsburgh and Cancer Institute, Pittsburgh, PA 15213
4 Molecular Therapeutics Drug Discovery Program, University of Pittsburgh Cancer Institute,
Pittsburgh, PA 15213
5 Department of Obstetrics, Gynecology, and Women’s Health, School of Medicine, University of
Pittsburgh, Pittsburgh, PA 15213
6 Gynecologic Oncology Research and Outreach Program, Magee Women’s Hospital, Pittsburgh,
PA 15213
7 Department of Mathematics, Carlow University, Pittsburgh, PA 15213
Abstract
Purpose—S-CKD602 is a pegylated liposomal formulation of CKD-602, a semi-synthetic
camptothecin analogue. Pegylated (STEALTH®) liposomes can achieve extended drug exposure
in plasma and tumor. Based on promising preclinical data, the first phase I study of S-CKD602
was performed in patients (pts) with refractory solid tumors.
Experimental Design—S-CKD602 was administered IV every 3 weeks. Modified Fibonacci
escalation was used (3–6 pts/cohort), and dose levels ranged from 0.1 to 2.5 mg/m2. Serial plasma
samples were obtained over two weeks and total (lactone + hydroxyl acid) concentrations of
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STATEMENT OF CLINICAL RELEVANCE
This study of S-CKD602 is the first phase I study of a pegylated-liposomal formulation of a camptothecin analogue and first
pharmacokinetic study evaluating the disposition of the liposomal encapsulated and released drug for a carrier formulation of a
camptothecin analogue. Evaluation of the pharmacokinetic disposition of the liposomal encapsulated verses released drug is of the
utmost importance because the liposomal encapsulated drug is an inactive prodrug. S-CKD602 showed manageable toxicity and
promising antitumor activity, especially in platinum-refractory ovarian cancer. The prolonged plasma exposure of encapsulated and
released CKD-602 over 1 to 2 weeks is consistent with STEALTH liposomes and provides extended exposure compared with non-
liposomal CKD-602. S-CKD602 also has pharmacologic advantages over other liposomal camptothecin agents. There is significant
inter-patient variability in the pharmacokinetic disposition of S-CKD602 and pharmacokinetic disposition of S-CKD is associated
with saturable clearance. These pharmacokinetic characteristics may also be associated with all liposomal and nanoparticle carrier
agents. The results of our current phase I study of S-CKD602 can be extrapolated to future clinical trials of S-CKD602 and other
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encapsulated, released, and sum total (encapsulated + released) CKD602 measured by LC-MS/
MS.
Results—45 pts (21 male) were treated: median age 62 years (range: 33–79 years); ECOG
status: 0 to 1 (43 pts) and 2 (2 pts). Dose-limiting toxicities of grade 3 mucositis occurred in 1/6
pts at 0.3 mg/m2, grade 3/4 bone marrow suppression in 2/3 pts at 2.5 mg/m2, and grade 3 febrile
neutropenia and anemia in 1/6 pts at 2.1 mg/m2. The maximum tolerated dose was 2.1 mg/m2.
Partial responses occurred in 2 pts with refractory ovarian cancer (1.7 and 2.1 mg/m2). High inter-
patient variability occurred in the pharmacokinetic disposition of encapsulated and released
CKD-602.
Conclusions—S-CKD602 represents a promising new liposomal camptothecin analogue with
manageable toxicity and promising antitumor activity. Phase II studies of S-CKD602 at 2.1 mg/m2
IV once every 3 weeks are planned. Prolonged plasma exposure over 1 to 2 wks is consistent with
STEALTH® liposomes and provides extended exposure compared with single doses of non-
liposomal camptothecins.
INTRODUCTION
S-CKD602 is a STEALTH® liposomal formulation of CKD-602, a camptothecin analogue
which inhibits topoisomerase I (1–3). The STEALTH® liposomal formulation consists of
phospholipids covalently bound to methoxypolyethylene glycol (mPEG) on the outside of
the lipid bilayer. Non-liposomal CKD-602 administered IV at 0.5 mg/m2/day for 5
consecutive days repeated every 21 days is approved in Korea for the treatment of newly
diagnosed small cell lung cancer and relapsed ovarian cancer (4–7).
The development of STEALTH® liposomes was based on the discovery that incorporation
of mPEG-lipids into liposomes yields preparations with prolonged plasma exposure and
superior tumor delivery compared to conventional liposomes composed of natural
phospholipids and non-liposomal agents (1,8,9). STEALTH® liposomal doxorubicin
(Doxil®) is approved for the treatment of refractory ovarian cancer, Kaposi sarcoma, and
multiple myeloma (10,11). Encapsulation of the CKD-602 in the acidic core of a
STEALTH® liposome should also protect the active-lactone form of the drug from being
converted to the inactive-hydroxy acid form in the blood and allow for release of the active-
lactone form into the tumor over a protracted period of time, which is ideal for a cell cycle-
specific drug (1–3,12–14). The clearance of non-pegylated and pegylated liposomes is via
the reticuloendothelial system (RES) (1,8,9,15,16). Once the drug is released from the
liposome the pharmacokinetic disposition will be the same as after administration of the
non-liposomal formulation of the drug (1,8,9,15,16).
The plasma exposure of S-CKD602 at 1 mg/kg IV × 1 was approximately 25-fold greater
than non-liposomal CKD-602 at 30 mg/kg IV × 1 in mice (3,6,15). In plasma, approximately
82% of CKD-602 was encapsulated inside of the liposome after administration of S-
CKD602 (3). In mice bearing human tumor xenografts, the duration of exposure of
CKD-602 in tumor was 3-fold longer for S-CKD602 compared with non-liposomal
CKD-602 (3). In addition, the antitumor response and therapeutic index were greater for S-
CKD602 compared with non-liposomal CKD-602 (3,6). These results are consistent with
reports that the antitumor response to camptothecin analogues is related to the duration of
time the drug concentration in tumor is above a critical threshold (3,6,12–14,17).
Therefore we conducted the first human phase I and pharmacokinetic study of S-CKD602.
The objectives in this study were to determine the maximum tolerated dose (MTD) of S-
CKD602, determine the toxicity profile of S-CKD602, and evaluate the pharmacokinetics
disposition of encapsulated, released, and sum total (encapsulated + released) CKD-602.
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Patients ≥ 18 years of age with a histologically or cytologically confirmed malignancy for
which no effective therapy was available were eligible for this study. Pertinent eligibility
criteria included a Eastern Cooperative Oncology Group (ECOG) performance status of 0 to
2, adequate bone marrow, hepatic, and renal function as evidenced by the following:
absolute neutrophil count (ANC) ≥ 1500/μL, platelets ≥ 100,000/μL, total bilirubin ≤ 1.5 x
upper limit of the institutional normal range (ULN), aspartate aminotransferase (AST) ≤ 1.5
x the ULN if liver metastases were not present and ≤ 4 x the ULN if liver metastases were
present, and absence of microscopic hematuria (18). Prior treatment with camptothecin
analogues other than S-CKD602 or non-liposomal CKD-602 was permitted. Written
informed consent, approved by the Institutional Review board of the University of
Pittsburgh Medical Center, was obtained from all patients prior to study entry.
Dosage and Administration
S-CKD602 is a formulation of CKD-602 encapsulated in long-circulating STEALTH®
liposomes. In S-CKD602, the STEALTH® liposome bilayer is composed of N-(carbonyl-
methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-phosphoethanolamine
(MPEG-DSPE) and 1,2-distearoyl-sn-glycero-phosphocholine (DSPC) in a molar ratio of
approximately 5:95. The mean particle diameter is approximately 100 nm, and CKD-602
encapsulation inside the liposomes exceeds 85%. S-CKD602 was supplied by ALZA
Corporation in sterile 10 mL single-use amber vials as a clear to slightly opalescent
suspension with a nominal total CKD-602 concentration of 0.1 mg/mL. S-CKD602 was
diluted 3-fold in 5% dextrose prior to administration. No pre-medications were administered
prior to S-CKD602.
S-CKD602 was administered IV over approximately 1 hour every 3 weeks. Doses
administrated, expressed in mg of CKD-602 per m2, were 0.10, 0.15, 0.20, 0.25, 0.30, 0.35,
0.40, 0.45, 0.50, 0.65, 0.85, 1.1, 1.7, 2.1, and 2.5 mg/m2. This phase I study followed a
standard dose escalation design with patients enrolled in cohorts of 3 initially, with the
possibility of extending the cohort up to 6 patients depending on the number of dose-
limiting toxicities (DLT) (18). No intra-patient dose escalation was permitted. The MTD
was defined as the dose below the dose at which 2 out of up to 6 patients experienced a
DLT. At the 2.5 mg/m2 dose level, 2 patients out of 3 experienced a DLT. Since the next
lower dose (1.7 mg/m2) dose level was associated with minimal toxicity, an additional
intermediate dose level of 2.1 mg/m2 was investigated.
Patient Assessment
Radiological response was measured by the Response Evaluation Criteria in Solid Tumors
(RECIST) every 2 cycles (19). Toxicity was assessed according to the National Cancer
Institute Common Terminology Criteria for Adverse Events version 3.01 and by relationship
to study drug. Dose limiting toxicities (DLT) were assessed during cycle 1. Hematologic
DLT’s were defined as: platelet count ≤25,000/mm3, ANC < 500/mm3 for ≥ 7 days, fever (≥
38.5°C) accompanied by ANC < 1000/mm3 and any other grade 3 or 4 hematologic event as
listed in CTCAE version 3.0. Other DLTs included any non-hematologic grade 3 or 4 event
that increased by ≥ 2 grades from baseline, with the exception of nausea, vomiting, alopecia,
weight change, fatigue, and infusion reactions. Complete blood counts were obtained
weekly and as medically indicated. The nadir and percentage decrease at nadir for the
1National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Instructions and Guidelines (Updated
August 9, 2006) Available from: http://www.fda.gov/cder/cancer/toxicityframe.htm.
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absolute neutrophil count (ANC), platelets, red blood cells (RBC), and monocytes were
estimated using standard methods (18,20,21).
Sample Collection, Processing, Analytical Studies, and Pharmacokinetic Analysis
Plasma samples for pharmacokinetic assessment were obtained from all patients. On cycle 1,
blood (7 mL) was collected in EDTA (purple top) tubes prior to administration, at end of the
infusion (approximately 1 h), and at 3 h, 5 h, 7 h, 24 h, 48 h, 72 h, 96 h, 168 h (day 8), and
336 h (day 15) after the start of the infusion. The blood samples were centrifuged at 1,380 x
g for 6 min. The plasma for the determination of the encapsulated and released CKD-602
was processed via solid phase separation as described previously (3). Plasma for the
determination of sum total (encapsulated + released) CKD-602 concentrations was placed in
a polypropylene sscrew-top tube and stored at −80°C until processed by acetonitrile
extraction as described previously (3). The encapsulated, released, and sum total CKD-602
concentrations were measured by a specific liquid chromatographic tandem mass
spectrometric assay (LC-MS/MS) as previously described (3). The total (lactone + hydroxy
acid) form of CKD-602 was measured for encapsulated, released, and sum total samples.
The lower limit of quantitation (LLQ) of the total form encapsulated, released, and sum total
CKD-602 were 2, 0.05, and 1 ng/mL, respectively.
The area under the encapsulated, released, and sum total CKD602 plasma concentration
versus time curve of the total form of CKD-602 form 0 to last measurable sample (AUC0-t)
and 0 to infinity (AUC0-∞) were calculated using the log trapezoidal method (22). The ratio
of released CKD-602 AUC to encapsulated CKD-602 AUC for each patient was calculated.
At doses of 1.7, 2.1, and 2.5 mg/m2, plasma samples for sum total CKD-602 were also
processed to measure the lactone and carboxylate forms of CKD-602 as previously
described (12–14,17). The lactone and carboxylate concentrations of sum total CKD-602
were measured via LC-MS/MS and the LLQ was 1 ng/mL for both forms. The percentage
CKD-602 lactone in each plasma sample was calculated as (lactone concentration divided
by the lactone concentration plus the carboxylate concentration) × 100).
Statistical Analysis
Comparisons between the nadir and percent decrease at nadir for ANC, platelets, RBC, and
monocytes on cycles 1, 2, 4, and 8 were performed using analysis of variance and multiple




Patient characteristics are summarized in Table 1. Forty-five patients were enrolled on this
study from September 29, 2003 to October 17, 2005 at University of Pittsburgh Cancer
Institute. All patients received at least one dose of drug and were evaluable for toxicity. A
total of 147 cycles were administered. The mean (range) number of cycles administered was
3.3 (1 to 12).
Toxicity
Drug-related toxicities are described in Table 2. Hematological toxicity was the most
common adverse event [grade 3 or 4 neutropenia occurred in 8 patients (18%), grade 3
anemia occurred in 4 patients (9%), and grade 3 or 4 thrombocytopenia occurred in 4
patients each (9%)]. DLT occurred at the dose of 0.3 mg/m2 (mucositis in 1 of 6 patients),
2.1 mg/m2 (anemia, febrile neutropenia in 1 of 6 patients) and 2.5 mg/m2 (neutropenia,
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anemia and thrombocytopenia in 2 of 3 patients). The MTD was defined as 2.1 mg/m2, due
to 2 of 3 patients experiencing DLT at the dose of 2.5 mg/m2. The relationship between
encapsulated and released CKD-602 AUC and DLT is depicted in Figures 1a and 1b,
respectively.
The cumulative toxicity of S-CKD602 as related to ANC, platelets, red blood cells (RBC),
and monocytes was evaluated. The nadir and % decrease at nadir for ANC, platelets, RBC,
and monocytes are presented in Table 3. The nadir and % decrease at nadir for ANC,
platelets, RBC, and monocytes were similar on cycles 1, 2, 4, and 8 (P > 0.05).
Response
Partial responses were documented in 2 (at 1.7 and 2.1 mg/m2) of 5 patients with ovarian
cancer. The 3 patients with ovarian cancer who did not respond were treated at 0.3, 2.1, and
2.5 mg/m2. The patients with ovarian cancer treated at 2.1 and 2.5 mg/m2 developed DLT in
cycle 1 and were not evaluated for response. Six patients (sarcoma (n = 3), hepato cellular (n
= 1), prostate (n = 1), and thyroid cancer (n = 1)) had stable disease that lasted for ≥ 6
cycles. The relationship between encapsulated and released CKD-602 AUC and response is
depicted in Figures 1a and 1b, respectively.
Pharmacokinetics
Pharmacokinetic sampling was initiated in all 45 patients enrolled on the study. The
relationship between S-CKD602 dose and encapsulated CKD-602 AUC is presented in
Figures 1a (log scale) and 2a (linear scale). There was significant variability in the
encapsulated AUC at each dose of S-CKD602 and a limited linear relationship between dose
and encapsulated AUC. At the MTD of 2.1 mg/m2, there was a 13.3-fold range in
encapsulated CKD-602 AUC. The encapsulated CKD-602 AUCs were similar from 0.1 to
1.1 mg/m2 and from 1.7 to 2.5 mg/m2; however from 1.1 to 1.7 mg/m2 there was a 7.7-fold
greater increase in the mean encapsulated AUC than in dose.
The relationship between S-CKD602 dose and released CKD-602 AUC is presented in
Figures 1b (log scale) and 2b (linear scale). There was significant variability in the released
AUC at each dose of S-CKD602 and a poor linear relationship between dose and released
AUC. At the MTD of 2.1 mg/m2, there was a 16.7-fold range in released CKD-602 AUC.
There is significant variability in the released AUC at each dose of S-CKD602 and a poor
linear relationship between dose and released AUC. The released CKD-602 AUCs were
similar from 0.10 to 0.85 mg/m2. However, the mean released CKD-602 AUC increased
2.1-fold from 0.85 to 1.1 mg/m2 and 3.8-fold from 1.7 to 2.1 mg/m2.
The encapsulated, released, and sum total CKD-602 AUCs and ratio of released AUC to
encapsulated AUC at each S-CKD602 dose are presented in Table 4. The encapsulated
CKD-602 AUC was similar to the sum total AUC at all doses. In addition, the encapsulated
AUC were significantly greater than the released AUC at all doses > 0.50 mg/m2. The ratio
of released CKD-602 AUC to encapsulated CKD-602 AUC decreased as the dose of S-
CKD602 was increased. The mean ratio of released CKD-602 AUC to encapsulated
CKD-602 AUC at S-CKD602 doses of 0.10 to 0.40 mg/m2, 0.50 to 1.10 mg/m2, and from
1.70 to 2.5 mg/m2 ranged from 0.14 to 0.71, 0.01 to 0.03, and 0.005 to 0.011, respectively.
The mean ± SD percentage lactone of sum total CKD-602 in each plasma sample at doses of
1.7, 2.1, and 2.5 mg/m2 were 97.4 ± 1.7 %, 97.9 ± 1.4 %, and 98.6 ± 0.7 %, respectively.
DISCUSSION
Major advances in the use of liposomes, conjugates, and nanoparticles as vehicles to deliver
drugs have occurred the past 10 years (1,8,9). STEALTH® liposomal doxorubicin (Doxil®)
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and albumin stabilized nanoparticle formulation of paclitaxel (Abraxane®) are now FDA
approved (10,11,24). In addition, there are greater than 100 liposomal and nanoparticle
formulations of anticancer agents currently in development (1). This is the first phase I and
pharmacokinetic study of a pegylated-liposomal formulation of a camptothecin analogue
and also the first to evaluate the pharmacokinetic disposition of the encapsulated and
released drug after administration of a liposomal or nanoparticle carrier formulation of a
camptothecin analogue (25,26,27). Evaluation of the pharmacokinetic disposition of the
liposomal encapsulated verses released drug is of the utmost importance because the
liposomal encapsulated drug is an inactive prodrug and thus only the released drug is active
(1,3). The prolonged plasma exposure of encapsulated and released CKD-602 over 1 to 2
weeks for S-CKD602 is consistent with STEALTH® liposomes and provides extended
exposure compared with non-liposomal CKD-602 and other liposomal formulations of
camptothecins (1–3,25–27).
S-CKD602 was well tolerated, and the overall incidence of grade 3 or 4 toxicity compared
favorably with other camptothecins (7,12,20,21,23,25–27). In contrast to irinotecan, patients
treated with S-CKD602 did not have grade 3 or 4 diarrhea (12,20,28). The incidence of
grade 3 or 4 neutropenia and neutropenic fever after administration of S-CKD602 compares
favorably to topotecan (12,20,29). In addition, the hematologic toxicity associated with S-
CKD602 was non-cumulative (12,20,29).
S-CKD602 exhibited promising antitumor activity with partial responses in two patients
with platinum refractory ovarian cancer and stable disease in 6 other patients with refractory
solid tumors. The two patients with platinum refractory ovarian cancer were treated at 1.7
and 2.1 mg/m2. Both patients were heavily pretreated and had previously received
STEALTH® liposomal doxorubicin (Doxil®) and the patient treated at 1.7 mg/m2 had
previously received topotecan. The patient treated at 1.7 mg/m2 had a partial response
confirmed after cycle 4 and was removed from the study after cycle 12 due to an increasing
CA-125. This patient also received topotecan in addition to other agents. The patient treated
at 2.1 mg/m2 had a partial response confirmed after cycle 6 and was removed from the study
after cycle 11 due to an increasing CA-125. Thus, studies of S-CKD602 in the treatment of
patients with ovarian cancer that is platinum refractory or sensitive ovarian cancer and in
patients with ovarian cancer who have failed Doxil and topotecan are warranted (28,30).
There was no direct relationship between antitumor response and the exposure of
encapsulated or released CKD-602. However, the two patients with partial responses had
encapsulated and released CKD-602 AUCs that were greater than the mean AUC for that
dose (Figures 1a and 1b). Moreover, four of the five evaluable patients with encapsulated
CKD-602 AUC > 30,000 ng/mL•h had a partial response (n = 2) or stable disease (n = 2).
The pharmacokinetic disposition of S-CKD602 is consistent with the STEALTH® concept
(1,8,9,15,16). After a single dose of S-CKD602 at the MTD of 2.1 mg/m2, the plasma
exposure of sum total CKD-602 was 68-fold higher compared with five daily doses of non-
liposomal CKD-602 at the MTD of 0.5 mg/m2/d (5,7). Patients treated at doses of S-
CKD602 ≥ 1.7 mg/m2 had quantifiable plasma concentrations of encapsulated and released
CKD-602 from 1 to 2 weeks after administration of a single dose of S-CKD602. The
encapsulated CKD-602 AUC was similar to the sum total AUC at all doses. In addition, the
encapsulated AUC were significantly greater than the released AUC at all doses > 0.50 mg/
m2. At dose < 0.50 mg/m2, the interpretation of encapsulated and released CKD-602 is
complicated by the lower LLQ for released (0.05 ng/mL) compared with encapsulated (2 ng/
mL) CKD-602 and that most concentrations of encapsulated and released drug were near or
below the LLQ. At the MTD of 2.1 mg/m2, the mean ± SD ratio of released CKD-602 AUC
to encapsulated CKD-602 AUC was 0.011 ± 0.004. This data suggests that most of the
CKD-602 remains encapsulated in the plasma after administration of S-CKD602. These
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results are also consistent with our previous studies of S-CKD602 in mice (3). Encapsulation
of the CKD-602 in the acidic core of the STEALTH® liposome also maintained CKD-602 in
the active-lactone form with the mean percentage lactone of > 97%.
There was significant inter-patient variability in the pharmacokinetic disposition of
encapsulated and released CKD-602 after administration of S-CKD602 (1,2). There was also
a poor relationship between the dose of S-CKD602 and the AUC of encapsulated and
released CKD-602. At low doses of S-CKD602 the variability of encapsulated CKD-602
were greater than at higher doses. At the MTD of 2.1 mg/m2, there was a 13-fold range in
encapsulated CKD-602 AUC. There is greater pharmacokinetic variability in encapsulated
CKD-602 compared with released CKD-602. This data suggests that the clearance of the
STEALTH® liposomal carrier is more variable than the released drug and ultimately
determines the overall exposure of drug in each patient (5,25–27). The high inter-patient
variability in the pharmacokinetic disposition of S-CKD602 is consistent with other
liposomal anticancer agents (5,25–27). Our data also suggests that S-CKD602 undergoes
non-linear or saturable clearance at higher doses (1,3). The clinical significance of these
differences and the factors associated with the pharmacokinetic variability need to be
evaluated for S-CKD602 and other liposomal and nanoparticle anticancer agents (1). As
most of the drug remains encapsulated in the pegylated liposome in plasma it appears that
the overall pharmacokinetic variability is associated with the clearance of the liposomal
carrier.
S-CKD602 exhibits all of the pharmacologic, antitumor, and cytotoxic advantages of a long
acting, liposomal anticancer agent (1–3,12,14,31). Thus, based on our prior preclinical
studies and the phase I study presented here, S-CKD602 warrants evaluation in phase II
studies in camptothecin sensitive tumors, especially ovarian, gastric and small cell lung
cancer, and potentially resistant tumors.
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Relationship between dose of S-CKD602 and encapsulated CKD-602 AUC0-∞. Figures 1a
and 2a represent the encapsulated AUC on a log and linear scale, respectively. S-CKD602
was administered at 0.10, 0.15, 0.20, 0.25, 0.30, 0.40, 0.50, 0.65, 0.85, 1.10, 1.70, 2.10, and
2.50 mg/m2. The patients with DLT are represented by the T. The patients with partial
response are represented by the PR. The patients with stable disease are represented by SD.
Two patients in each dose level treated at 0.10, 0.15, and 0.85 mg/m2 had 1 to 2 detectable
concentrations of encapsulated CKD-602 and thus an accurate encapsulated CKD-602 AUC
could not be calculated for these patients. The patients treated at 2.5 mg/m2 had limited
pharmacokinetic sampling due to toxicity and logistical issues. The patients treated at 2.5
mg/m2 with the highest, medium, and lowest AUCs were calculated from 0 to 96 h, 0 to 48
h, and 0 to 96 h, respectively.
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Relationship between dose of S-CKD602 and released CKD-602 AUC0-∞. Figures 1b and
2b represent the released AUC on a log and linear scale, respectively. S-CKD602 was
administered at 0.10, 0.15, 0.20, 0.25, 0.30, 0.40, 0.50, 0.65, 0.85, 1.10, 1.70, 2.10, and 2.50
mg/m2. The patients with DLT are represented by the T. The patients with partial response
are represented by the PR. The patients with stable disease are represented by SD. The
patients treated at 2.5 mg/m2 had limited pharmacokinetic sampling due to toxicity and
logistical issues. The patients treated at 2.5 mg/m2 with the highest, medium, and lowest
AUCs were calculated from 0 to 96 h, 0 to 48 h, and 0 to 96 h, respectively.
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Male/Female Enrolled (n) 21/24




 Range 33 – 79





 Colorectal Adenocarcinoma 17
 Ovarian Cancer 5
 Sarcoma 5
 Non-Small Cell Lung Cancer 4
 Pancreatic Adenocarcinoma 3
 Hepatocellular Carcinoma 2
 Prostate Carcinoma 2
 Esophageal, Metastatic Breast, Mesothelioma, Renal Cell Carcinoma, Thyroid, Appendix, Unknown Primary 1 patient for each tumor type
Prior Treatments
 Median 3
 Range 1 – 9
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Table 2
Common Drug-Related Adverse Events by Maximal Severity for All Cycles
Adverse Events a Grade 1 Grade 2 Grade 3 Grade 4
Anemia 3 6 4 0
Neutropenia 3 2 5 3
Thrombocytopenia 4 1 3 1
Diarrhea 12 0 0 0
Nausea 20 4 1 0
Vomiting 6 2 1 0
Anorexia 5 3 0 0
Fatigue 12 8 3 0
Pyrexia 3 2 0 0
a
Patients were counted once per cycle for the most severe of multiple drug-related occurrences of a specific MedDRA preferred term.
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